CSC swung to a fiscal third-quarter loss on a $1.49 billion write-down of its investment in a disputed contract with the U.K.'s state-run health service.

However, adjusted earnings were better than anticipated, pushing shares up 2% to $26.99 in recent premarket trading. Through the close, the stock is down 53% in the past year.

New business awards totaled $4.1 billion, up from $2.3 billion a year earlier.